Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

Nasdaq Inc. Chief Executive Officer Adena Friedman said she expects a strong environment for initial public offerings in the second quarter and balance of 2025 as investors gain confidence from ...

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

Nasdaq reported higher fourth-quarter profit on Wednesday, helped by increased demand for the exchange operator's financial ...

Sports bar and restaurant chain Twin Peaks goes live on Nasdaq today. Inspire Brands and Panera Brands could be next in line ...

Thursday marked the Nasdaq Global Market debut of Beta Bionics, Inc. as its initial public offering (IPO) opened for trading ...

IPO activity is projected to increase in 2025, fueled by anticipated policy changes under Trump and a more favorable business climate. According to Reuters, investment bankers are preparing for a ...